Find, compare & contact
Diphemanil
API Manufacturers & Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Diphemanil API 15394-62-4?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Diphemanil. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Diphemanil
- Synonyms:
- Diphemanil cation , Diphemanil ion
- Cas Number:
- 15394-62-4
- DrugBank number:
- DB13720
- Unique Ingredient Identifier:
- Q26TX1UD0W
General Description:
Diphemanil is a chemical compound identified by the CAS number 15394-62-4. It is known for its distinct pharmacological properties and applications.
Indications:
This drug is primarily indicated for: Used in the treatment of peptic ulcer, gastric hyperacidity, and hypermotility in gastritis and pylorospasm, and in the treatment of hyperhidrosis (excessive perspiration). Its use in specific medical scenarios underscores its importance in the therapeutic landscape.
Absorption:
The absorption characteristics of Diphemanil are crucial for its therapeutic efficacy: Poorly absorbed from the gastrointestinal tract with an absolute bioavailability of 15 to 25%. The drug's ability to rapidly penetrate into cells ensures quick onset of action.
Pharmacodynamics:
Diphemanil exerts its therapeutic effects through: Diphemanil Methylsulfate is a quaternary ammonium anticholinergic. It binds muscarinic acetycholine receptors and thereby decreases secretory excretion of stomach acids as well as saliva and sweat. The drug's ability to modulate various physiological processes underscores its efficacy in treating specific conditions.
Mechanism of Action:
Diphemanil functions by: Diphemanil Methylsulfate exerts its action by primarily binding the muscarinic M3 receptor. M3 receptors are located in the smooth muscles of the blood vessels, as well as in the lungs. This means they cause vasodilation and bronchoconstriction. They are also in the smooth muscles of the gastrointestinal tract (GIT), which help in increasing intestinal motility and dilating sphincters. The M3 receptors are also located in many glands which help to stimulate secretion in salivary glands and other glands of the body. This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.
Classification:
Diphemanil belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups, classified under the direct parent group Diphenylmethanes. This compound is a part of the Organic compounds, falling under the Benzenoids superclass, and categorized within the Benzene and substituted derivatives class, specifically within the Diphenylmethanes subclass.
Categories:
Diphemanil is categorized under the following therapeutic classes: Agents producing tachycardia, Alimentary Tract and Metabolism, Anti-Asthmatic Agents, Anticholinergic Agents, Autonomic Agents, Bronchodilator Agents, Drugs for Functional Gastrointestinal Disorders, Muscarinic Antagonists, Parasympatholytics, Peripheral Nervous System Agents, Respiratory System Agents, Synthetic Anticholinergics, Quaternary Ammonium Compounds. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Diphemanil is a type of Anti-asthma
Anti-asthma pharmaceutical APIs are a category of active pharmaceutical ingredients (APIs) specifically developed to combat asthma, a chronic respiratory condition characterized by inflammation and narrowing of the airways. These APIs play a crucial role in the formulation of effective medications used to manage and treat asthma symptoms.
The primary objective of anti-asthma pharmaceutical APIs is to alleviate airway inflammation and bronchospasms, which are the major factors contributing to asthma attacks. These APIs target specific cellular receptors involved in the inflammatory response, such as leukotriene receptors and beta-2 adrenergic receptors.
Corticosteroids are a common class of anti-asthma APIs used to suppress inflammation in the airways. They work by inhibiting the production of inflammatory molecules, thereby reducing swelling and mucus production. Beta-2 agonists are another essential group of APIs that act on the beta-2 adrenergic receptors in the airway smooth muscles, leading to relaxation and opening of the airways.
Anti-asthma APIs are carefully synthesized and purified to meet stringent quality standards, ensuring their safety and efficacy. Extensive research and development efforts go into optimizing the pharmacological properties of these APIs, including their bioavailability, stability, and compatibility with different formulations.
Pharmaceutical companies utilize anti-asthma APIs to develop various dosage forms, including inhalers, tablets, and injections. These APIs are often combined with other excipients and technologies to enhance drug delivery and improve patient compliance.
In conclusion, anti-asthma pharmaceutical APIs are critical components in the development of medications that effectively manage asthma symptoms. They target key mechanisms underlying asthma pathophysiology, providing relief from airway inflammation and bronchospasms. These APIs enable the formulation of safe and efficient anti-asthma drugs, empowering individuals with asthma to lead healthier lives.
